Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of cervical cancer globally
3.2.1.2 Growing government initiatives to spread disease awareness
3.2.1.3 Rising incidence of HPV infections
3.2.1.4 Increase in R&D funding for cancer research
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects associated with the treatment
3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Gap analysis
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Squamous cell carcinoma
5.3 Adenocarcinoma
5.4 Adenosquamous carcinoma
Chapter 6 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Prevention
6.2.1 Gardasil/gardasil9
6.2.2 Cervarix
6.3 Treatment
6.3.1 Avastin
6.3.2 Keytruda
6.3.3 Generics
6.3.4 Other treatments
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AbbVie Inc.
9.2 AstraZeneca PLC
9.3 Biocon Limited
9.4 Mylan N.V.
9.5 Bristol-Myers Squibb Company
9.6 Eli Lilly And Company
9.7 F. Hoffmann-La Roche Ltd
9.8 Fresenius SE & Co. KGaA
9.9 GSK plc
9.10 Hikma Pharmaceuticals PLC
9.11 Mckesson Corporation
9.12 Merck & Co., Inc.
9.13 Pfizer Inc.
9.14 Sandoz Group AG
9.15 Xiamen Wantai Canghai Biotechnology Co., Ltd.
